Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00515216 · ClinicalTrials.gov registry record · Phase 2
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors
A Phase 2 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00515216 is a Phase 2 study that has completed, run by Vanderbilt University. The registered enrollment target is 26 participants.
The verdict
NCT00515216, a Phase 2 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study is for patients who have stomach cancer or cancer of the lower part of the esophagus that has spread to other organs. There are many different chemotherapy treatments for this type of cancer. At the present time, there is no general agreement on the way to choose the most beneficial therapy for an individual patient. Patients with different genetic backgrounds may respond differently to the same chemotherapy treatments. In this study the investigators will use a certain genetic difference in an important gene (thymidylate synthase or TS gene) to see whether treating patients who have a particular type of that gene will respond better to a standard chemotherapy regimen. The investigators are hoping that by treating patients according to their genes, that they may respond to treatment of their cancer better and it will help the investigators choose cancer treatments better in the future.
Interventions
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG 5-fluorouracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-08 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00515216
The ClinicalTrials.gov registry entry for NCT00515216 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Leucovorin is the first listed.
NCT00515216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00515216 about?
NCT00515216 is a clinical study titled "Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors". This study is for patients who have stomach cancer or cancer of the lower part of the esophagus that has spread to other organs. There are many different chemotherapy treatments for this type of cancer. At the present time, there is no general agreement on the way to choose the most beneficial thera...
What is the current status of trial NCT00515216?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2007-08. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00515216?
The interventions under investigation include: Leucovorin (DRUG), Oxaliplatin (DRUG), 5-fluorouracil (DRUG).
Who is sponsoring clinical trial NCT00515216?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.